A closed loop drug discovery process
Ad Atomica's proprietary platform represents a paradigm shift in pharmaceutical development. By harnessing advanced artificial intelligence and iterative optimisation, we've created a seamless, circular workflow that transforms target identification into validated lead candidates at unprecedented speed and cost efficiency.
Our closed loop system integrates computational design with experimental validation, enabling rapid iteration and continuous learning. Each cycle refines our models, enhancing predictive accuracy and accelerating the path from concept to candidate. This approach eliminates the bottlenecks that plague traditional drug discovery, where linear workflows and disconnected stages create costly delays.
Key Advantages of Our Platform
Multi-Parameter Optimisation
Our AI simultaneously optimises for drug likeness, ADMET properties, target affinity, and selectivity eliminating traditional trade-offs between potency and pharmaceutical viability.
Atom-by-Atom Construction
Unlike template based approaches, we build molecules from first principles, exploring vast chemical space to discover novel scaffolds that conventional methods would miss entirely.
Continuous Learning Loop
Every synthesis and assay result feeds back into our models, creating a virtuous cycle where each iteration improves our predictive power and design sophistication.
The result is a fundamentally more efficient discovery engine. Where traditional medicinal chemistry programmes might screen thousands of compounds over years, Ad Atomica's platform designs highly optimised candidates in weeks, dramatically reducing both time-to-clinic and development costs whilst maintaining rigorous scientific standards.
The Team
Ad Atomica's founding team combines entrepreneurial execution, deep technical expertise, and scientific rigour. Together, we're building the future of computational drug discovery with a pragmatic, results-driven approach.
Adam Davis
Chief Executive Officer
Adam leads Ad Atomica's commercial strategy, partnerships, and overall execution. He brings a founder's track record of delivering complex, capital-intensive projects at pace, having previously built a company that developed over £30 million of real estate across the United Kingdom.
In early 2025, a personal experience using large language models to interpret clinical signals during his father's hospitalisation sparked Adam's fascination with AI-driven medicine. This pivotal moment led him to explore the transformative potential of artificial intelligence in healthcare and subsequently assemble Ad Atomica's exceptional team.
Lygon Bowen-West
Chief Technology Officer
Lygon is a full-stack engineer with seven years' experience building robust, scalable systems. His background includes two years automating bioinformatics pipelines for research scientists, giving him unique insight into the computational challenges facing modern drug discovery.
At Ad Atomica, Lygon architects and develops our entire technology platform, ensuring our AI systems are production-ready, scientifically rigorous, and capable of handling the computational demands of real-world pharmaceutical development.
Alex Dean
Chief Research Officer
Alex brings a formidable research pedigree to Ad Atomica, holding a PhD in artificial intelligence and a master's degree in theoretical physics. This combination of deep learning expertise and fundamental scientific training positions him uniquely to tackle the complex challenges of computational molecular design.
With two years' experience at an AI consulting startup, Alex seamlessly bridges the gap between cutting-edge research and practical implementation, building the machine learning systems that power Ad Atomica's discovery platform.
Scientific Advisory Board
Our scientific advisers provide world-class expertise in oncology therapeutics and synthetic chemistry, ensuring Ad Atomica's platform meets the rigorous standards of pharmaceutical development.
Oncology Expert
Professor Charles Coombes
A renowned oncologist with decades of experience in cancer therapeutics development and approximately 50,000 scientific citations, Professor Coombes brings unparalleled clinical and translational expertise to Ad Atomica.
He was part of the pioneering team that developed Samuraciclib, a CDK7 inhibitor, demonstrating his deep understanding of targeted cancer therapy development. Professor Coombes FMedSci is Emeritus Professor of Medical Oncology at Imperial College London.
Chemistry Expert
Professor Till Opatz
Internationally recognised for groundbreaking research in natural products synthesis and organic chemistry with approximately 10,000 scientific citations, Professor Opatz ensures our designed molecules are synthetically accessible and scalable.
His specialisation in the design and scalable synthesis of bioactive molecules is crucial for translating Ad Atomica's computational designs into real-world drug candidates. Professor Opatz's expertise bridges the gap between in silico prediction and practical chemistry, a critical capability for any AI-driven discovery platform.
Strategic Partnerships
Ad Atomica is actively exploring collaborative partnerships with leading academic institutions and pharmaceutical companies. We believe the future of drug discovery lies in combining computational innovation with established expertise in target biology, medicinal chemistry, and clinical development.
Academic Collaborations
Partner with us to access cutting-edge AI capabilities whilst advancing fundamental research in computational chemistry and drug design.
Industry Partnerships
Accelerate your discovery programmes with our platform, reducing timelines and costs whilst exploring novel chemical space for your therapeutic targets.
Target Specific Programmes
Co develop programmes in oncology, immunology, or other therapeutic areas where rapid, cost effective lead generation creates strategic advantage.
Get in Touch
We welcome conversations with investors, pharmaceutical partners, and academic collaborators who share our vision of transforming drug discovery through artificial intelligence. Whether you're interested in partnership opportunities, investment discussions, or simply learning more about our platform, we'd be delighted to connect.